Spontaneous closure of FTMH after vitrectomy for VMT

Article

In this article, the authors summarize a recently published case study of a macular hole formation and its spontaneous closure after vitrectomy.

In our clinic we experienced a case of a macular hole formation and its spontaneous closure after vitrectomy for VMT, which we have recently published.1 In this article, we will present a brief summary of this case report and our findings.

Case presentation

A week after vitrectomy we found, using SD-OCT examination (Spectralis, Heidelberg Engineering, Heidelberg, Germany), that the VMT had resolved but a full-thickness macular hole (FTMH) had formed. A month later the FTMH had spontaneously closed, and after another 5 months, SD-OCT showed a normal foveal contour.

First description

The current case is, to the best of our knowledge, the first description of macular hole formation and spontaneous closure after vitrectomy for VMT that is clearly documented step-by-step with SD-OCT.

The formation of FTMH may have been a result of the creation of anterio-posterior traction on the fovea by the posterior hyaloid membrane, in addition to, damage caused to the retinal layer in the macular area during detachment.

In this case, the traction was pulled up to the retina, so that the edges of the hole were elevated high, but it was stabilized by the ILM and the posterior hyaloid membrane during surgically induced detachment. The complex of the posterior hyaloid membrane and ILM was probably removed in the macular area and FTMH developed.

Conclusion

FTMH may develop in its natural course and after vitrectomy for VMT.2,3 However, in these referenced cases there was no spontaneous closure of the FTHM, they all required further surgery to close the macular hole.

The release of the mechanical traction may be the main reason for the eventual closure of the macular hole. However, ILM peeling induces glial cell proliferation across the hole and this mechanism may also help the spontaneous closure of macular hole.

References

1. D. Odrobina et al., BMC Ophthalmology, 2014;14:17.

2. N. Yamada et al., Am. J. Ophthalmol., 2005;139(1):112–117.

3. D. Odrobina et al., Retina, 2011;31(2):324–331.

Recent Videos
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.